No title
Maternal alloantibody-induced hemolytic disease of the fetus and newborn (HDFN) remains a significant concern worldwide. Alloimmune HDFN can be pathogenetically named by the specific alloantibodies involved. Moreover, four mechanistic pathway types are generally recognized in clinical practice: classical or extravascular hemolysis; immune-pressure-escaped, also known as antibody-mediated antigen-m
